Article
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
Cancer cell - 14 May 2018
Hellmann Matthew D, Callahan Margaret K, Awad Mark M, Calvo Emiliano, Ascierto Paolo A, Atmaca Akin, Rizvi Naiyer A, Hirsch Fred R, Selvaggi Giovanni, Szustakowski Joseph D, Sasson Ariella, Golhar Ryan, Vitazka Patrik, Chang Han, Geese William J, Antonia Scott J
Abstract excerpt
Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on efficacy of nivolumab monotherapy or combined with ipilimumab in patients with SCLC from the nonrandomized or randomized cohorts of CheckMate 032....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.